Summary There is considerable interest in immunohistochemical markers of proliferation which are suitable for use on routinely fixed clinical material. The novel proliferation-associated antibody Ki-SI shows promise in this respect. In this study we have: (i) defined the pattern of Ki-Si labelling relative to the cell cycle phase; (ii) investigated the labelling pattern with Ki-Si on a human breast cell line (ZR75) under varying proliferative conditions induced by serum deprivation and refeeding; (iii) examined in a flow cytometric study Ki-Sl staining in archival, clinical breast carcinoma samples. In exponentially growing cells Ki-S1 showed a marked cell cycle phase-specific variation in staining intensity which increased linearly through the S-phase, was high in G2 and reached its peak in mitosis. Ki-Si staining intensity mirrored the changes in proliferative activity of ZR75 cells during serum deprivation and refeeding. In a small series of human breast carcinomas, Ki-S1 staining intensity correlated with S-phase fraction (SPF) derived from DNA profiles. The (Quinn & Wright, 1990 Probably the most popular immunohistological marker of proliferative activity so far has been the monoclonal antibody Ki-67 (Gerdes et al., 1983). This antibody has also been used to detect proliferative cells by flow cytometry (Baisch et al., 1987) . A major drawback of this antibody is that the epitope which it labels is extremely labile and does not withstand conventional fixation procedures. 
Many proteins are involved in the process of cell proliferation and some of them have a regulatory role. Identification and characterisation of proliferation-related proteins may give insight into important aspects of cell and tumour biology. In addition, the ability to use such proteins as markers of proliferative activity may be of practical use in clinical situations.
Traditionally, proliferation has been assessed by methods involving the incorporation of tritiated thymidine (3H-TdR) or by techniques based on mitotic counting. The use of 3H-TdR has the disadvantages, for clinical situations, of involving a radioactive isotope and requiring the relatively laborious technique of autoradiography to detect labelled cells. Nevertheless, 3H-TdR labelling has yielded clinically useful data (see for example Silvestrini et al., 1989) . Mitotic counting suffers from being extremely laborious if performed correctly, requiring large numbers of cells to be counted since mitosis is a relatively rare event (Quinn & Wright, 1990) . DNA flow cytometry is quick and statistically precise and can yield very useful data (see for example O'Reilly et al., 1990) . However, it does require an expensive piece of equipment and may not be applicable for very small lesions or situations in which retention of tissue morphology is of particular importance. Thus, the immunohistological method of assessing proliferation by detecting the presence of proliferation-related proteins is appealing. Tissue architecture is maintained, the methodology is relatively simple and the use of radioactivity is avoided. However, to be useful as a clinical marker of proliferation, a protein must be robust, its presence must given unambiguous information about proliferative state and the results obtained should give useful insight into the clinical course of the disease.
Probably the most popular immunohistological marker of proliferative activity so far has been the monoclonal antibody Ki-67 (Gerdes et al., 1983) . This antibody has also been used to detect proliferative cells by flow cytometry (Baisch et al., 1987) . A major drawback of this antibody is that the epitope which it labels is extremely labile and does not withstand conventional fixation procedures. It can thus only be used on frozen tissue. Antibodies directed against other cell cycle related proteins have been used as proliferation markers in recent years. There has been particular interest in antibodies against proliferating cell nuclear antigen (PCNA), a protein which functions as an auxiliary factor to DNA polymerase 6 (Lee et al., 1989) . One such antibody called PCI0 has recently become commercially available and it has the advantage of labelling cells in routinely fixed clinical material. It has been shown to give useful information about proliferative activity in a range of normal tissues and in some tumours (Hall et al., 1990; Yu et al., 1991) . However, in a number of types of carcinoma, for example breast, results with PC10 have not correlated either with other proliferative markers or with clinical outcome (Leonardi et al., 1992; Gillett et al., 1992) .
In the present study, we have used the power of multiparametric flow cytometry to define the nature of labelling seen with a new proliferation-related antibody, Ki-Sl Metaphase-arrest experiment Cells were plated in Falcon flasks and in petri-dishes. (Camplejohn et al., 1989 (Figure 2 and Table I ) with a virtual disappearance of strongly labelled cells by 7 days of serum deprivation. Only residual weak labelling is seen with Ki-SI at this time. Following refeeding with medium containing 10% serum, there was a recovery in the intensity of staining. Thus 7 days after refeeding with 10% serum, staining intensity with Ki-Sl had returned close to normal levels.
Staining in GI cells is weak even in exponentially growing cells and thus these cells have little scope to show a reduction in Ki-Sl staining intensity during serum deprivation. In contrast, not only do the numbers of S and G2/M cells reduce during serum deprivation, but also the intensity of staining in these cells cycle phases shows marked reduction (Table I) .
Metaphase-arrest experiment This experiment was performed for two reasons. First and foremost was to explain the small tail of relatively strongly labelled G, cells shown in region 2 (R2) of the first plot in Figure 3 . This plot illustrates Ki-Sl labelling in control exponentially-growing ZR75 cells. About 5% of all GI cells show strong Ki-Sl labelling and are found in R2 of this plot. We had suspected that these were cells which had recently left mitosis. This supposition is supported by the finding that 2 h after addition of vincristine (VCR), the number of GI cells in R2 was reduced by a factor of five and by 4 h after VCR (second plot in Figure 3 ) R2 is effectively empty and remains empty until the end of the experiment (final plot of Figure 3 ).
Over the same time course there is an increase of cells with a G2/M DNA content and most of these cells fall in R3 of the plots in Figure 3 . The increase in cells in R3 (i.e. the most strongly Ki-Sl positive cells) is in good agreement with the expected that detergent treatment would lead to loss of mitotic cells. However, parallel samples from non-detergent treated cells were run and gave the same results. Further, the result from the flow cytometry of detergent-treated cells was in good agreement with microscopic counts.
Ki-SJ staining of clinical breast cancer samples
It is clear from the data presented here and from other studies we have performed, that Ki-SI gives strong staining even on nuclei extracted from sections of paraffin-embedded clinical material. S-phase fraction (%) Figure 5 The SPF (%) is plotted against the mean fluorescence intensity of staining with Ki-S1 for fifteen cases of carcinoma of the breast. Figure 5 ) with a linear regression analysis yielding a correlation coefficient of 0.5 (P = 0.03). This is despite one outlying sample (case 15- Table I ) which had the highest SPF value but a low intensity of Ki-SI staining. This particular tumour exhibited a very high level of necrosis on tissue sections. Excluding this case the correlation is considerably stronger (r = 0.8;
P<0.001).
A consistent finding was that in aneuploid tumours, staining was stronger in the aneuploid component than in the diploid component.
Discussion
The results of this study concerning the use of PC1O after detergent extraction to detect S-phase cells are in good agreement with earlier reports (Landberg & Roos, 1991; Wilson et al., 1992 (Figure 2 and Table I ). Thus throughout this experiment staining intensity with this antibody reflected the changes in proliferative activity as defined by BrdUrd labelling, SPF and PCIO labelling.
As Ki-Si is a novel antibody, there are no previous flow cytometric studies available. Data in Figure 2 and Table I show that this antibody exhibits a marked cell cycle phase specific staining pattern with G2/M cells being approximately four times more strongly labelled on average than GI cells.
However, it can be seen in Figure 2 , that the staining pattern is quite complex with a small percentage of GI cells exhibiting quite strong labelling and labelling in G2/M being heterogeneous. This staining pattern shows marked similarities with that previously described for another proliferation-related antibody Ki-67 (Landberg et al., 1990 Staining intensity in most GI cells is fairly weak. Staining intensity increases linearly through S-phase, is high in G2 and reaches its peak in mitosis. Despite the similar pattern of labelling displayed by Ki-SI and Ki-67, the limited evidence available so far does not suggest that the antigens which they label are identical. Despite recent progress (Gerdes et al., 1991) , the antigen labelled by Ki-67 has not been directly identified due to its extreme lability but it would seem to be a large molecule consisting of two parts of 345 and 395 kD. Preliminary evidence suggests that the Ki-SI antigen, also as yet unidentified, has a much smaller molecular weight (Kreipe et al., 1992) . However, at this preliminary stage, it can clearly not be ruled out that the antigens for Ki-67 and Ki-SI are related if not identical.
The experience with immunohistochemical detection of proliferation-related proteins in breast cancer is mixed. The anti-PCNA monoclonal antibody PC1O has the advantage of working on paraffin-embedded material. Unfortunately, staining with PC1O in breast carcinoma does not seem to correlate with other clinicopathological variables such as tumour grade, steroid receptor content and other proliferative markers (Leonardi et al., 1992) . Nor from our own studies does PCIO labelling predict clinical outcome (Gillett et al., 1992) . In contrast, a number of studies have found a correlation between Ki-67 staining and a variety of clinicopathological variables (Crispino et al., 1989; Isola et al., 1990; Leonardi et al., 1992) . In addition, some small studies suggest a prognostic role for Ki-67 staining in breast cancer (Bouzubar et al., 1989; Gasparini et al., 1989; Wintzer et al., 1991) . Unfortunately most of these studies are on small cohorts of patients and with short follow-up. A principal disadvantage with Ki-67, however, is that it requires frozen material. In the present pilot study, Ki-Sl labelling was found to correlate with SPF. Further Ki-SI labelling detected immunohistochemically on tissue sections has been found to be a strong predictor of clinical outcome in breast cancer (Sampson et al., 1992a,b) . An important characteristic of the antigen labelled by Ki-SI is its extreme resistance to degradation. In the present study, strong Ki-SI labelling was seen in nuclei which had undergone routine histological fixation and processing, followed by an aggressive disaggregation procedure involving low pH and concentrated pepsin digestion.
In summary, early results with Ki-Si from this and other studies support its role as a proliferative marker, which is of prognostic value in breast cancer. Although results with Ki-SI are clearly preliminary, the epitope which it labels is extremely robust. Further, in this study, the labelling seen with ZR75 cells was clearly proliferation-related. In a small series of breast carcinomas, Ki-S1 labelling correlated with S-phase fraction determined from DNA profiles.
